Pregled bibliografske jedinice broj: 1032672
P050 Serum adropin levels in patients with Crohn’s disease
P050 Serum adropin levels in patients with Crohn’s disease // Journal of Crohn's and Colitis
Kopenhagen, Danska, 2019. str. S111-S111 doi:10.1093/ecco-jcc/jjy222.174 (poster, podatak o recenziji nije dostupan, sažetak, znanstveni)
CROSBI ID: 1032672 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
P050 Serum adropin levels in patients with Crohn’s disease
Autori
Zivkovic, P M ; Tadin Hadjina, I ; Rusic, D ; Vilovic, M ; Supe-Domic, D ; Martinovic, D ; Puljiz, Z ; Tonkic, A ; Bozic, J
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Journal of Crohn's and Colitis
/ - , 2019, S111-S111
Skup
14th Congress of European Crohn´s and Colitis Organization
Mjesto i datum
Kopenhagen, Danska, 06.03.2019. - 09.03.2019
Vrsta sudjelovanja
Poster
Vrsta recenzije
Podatak o recenziji nije dostupan
Ključne riječi
Crohn's disease, adropin
Sažetak
Background Crohn’s disease is a chronic inflammatory condition that primarily affects the gastrointestinal tract, with high possibility of systemic complications. Adropin is a novel discovered protein highly expressed in various organ systems that has an important role in energy homeostasis, metabolic control and intercellular communication. Adropin could be involved in the pathogenesis of number of diseases, according to the fact that different studies connected low adropin levels with metabolic syndrome, insulin resistance, coronary disease and heart failure. The main aim of this study was to compare serum adropin levels in patients with Crohn’s disease and matched control subjects. Furthermore, additional goal was to investigate relationship between adropin and other standard biochemical parameters, and anthropometric measurements as well. Methods In this study, 40 patients with Crohn’s disease were enrolled (23 males and 17 females), as well as 40 age- and gender-matched control subjects. Serum adropin levels was measured by ELISA kit (Phoenix Pharmaceuticals), while other biochemical parameters were determined with standard laboratory procedures. Detailed anamnestic data and anthropometric measurements were taken from each participant. Results Crohn’s disease group had significantly lower serum adropin levels when compared with controls (2.13 ± 0.47 vs. 3.02 ± 0.55 ng/ml ; p = 0.001). Regarding other biochemical parameters, there was no statistical significance in concentrations of glucose, total cholesterol, HDL, LDL and triglycerides between study and control group, while CRP levels were significantly higher in Crohn’s disease group (20.12 ± 18.36 vs. 1.78 ± 1.56 mg/l ; p = 0.001). Adropin showed significant positive correlation with both LDL (r = 0.373, p = 0.014) and HDL (r = 0.341, p = 0.023) concentrations, while significant negative correlation was found between adropin and CRP (r = −0.368, p = 0.019). Conclusion Our study demonstrated lower serum adropin levels in patients with Crohn’s disease in comparison to controls. It is possible that adropin has a role in the complex pathophysiology of Crohn’s disease. However, more investigations are necessary for further clarification of that connection.
Izvorni jezik
Engleski
Znanstvena područja
Temeljne medicinske znanosti
POVEZANOST RADA
Ustanove:
KBC Split,
Medicinski fakultet, Split
Profili:
Joško Božić
(autor)
Daniela Šupe Domić
(autor)
Ante Tonkić
(autor)
Marino Vilović
(autor)
Doris Rušić
(autor)
Željko Puljiz
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- Scopus
- MEDLINE